Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current therapies include treatment and secondary prophylaxis with anticoagulants, as well as acute treatment with thrombolytics in the case of severe events such as PE. Among all anticoagulant drugs, non-vitamin K antagonist oral anticoagulants (NOACs) have gained popularity in recent years and have become drivers of market growth. Nonetheless, low-molecular-weight heparins (LMWHs) are still widely prescribed. This analysis of claims data provides a quantitative picture of prescribing patterns for newly diagnosed and recently drug-treated VTE patients in the United States.
Market covered: United States
Key companies: Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Mylan, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Genentech
Key drugs: Dabigatran etexilate mesylate, argatroban, dalteparin sodium, enoxaparin sodium, heparin sodium, fondaparinux sodium, apixaban, edoxaban, rivaroxaban, warfarin, alteplase
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.